Number of UK patient groups saying pharma has 'good' or 'excellent' reputation has fallen, according to survey

About The Authors

2nd October 2019 13:15 - Pharmaceutical

Number of UK patient groups saying pharma has 'good' or 'excellent' reputation has fallen: A survey of patient groups across 50 specialities in the UK, has found a decrease in the number of patient groups awarding pharma companies a 'good' or 'excellent' rating.

Senior executives from 111 UK patient groups took part in the global 2018 Corporate Reputation survey on behalf of their patients. 

Respondents were asked to rank companies using 12 indicators which included supplying high-quality useful products, being transparent about, and sharing the results of clinical trials, as well as acting with integrity. 

The latest research revealed a decrease in the number of UK patient groups saying pharma had an 'excellent' or 'good' reputation from 32% in 2017 to 28% in the latest poll. 

It also found that just 43% of the UK patient groups taking part had worked with a pharmaceutical company, which is down from 64% the previous year.

Looking at why fewer patient groups in the 2018 report gave pharma companies a 'good' or 'excellent' rating, Brexit was one reason cited by the analyst. 

The research took place between November 2018 to February 2019 and reviewed 19 pharma companies including Pfizer, AstraZeneca, GSK, Gilead and Sanofi.

The survey found than Gilead was ranked the highest overall for corporate reputation out of all pharmaceutical companies included in the study, for the 18 patient groups familiar with it, as well as ranking top for patient-group engagement, involvement of patients in R&D and high-quality patient information. 

Janssen was the second highest ranking company by the 29 patient groups familiar with it - a leap of eleven places since last year.   

Novartis came in third overall, ranked by the 64 patient groups who have had experience of the company, while MSD was ranked fourth by the 55 groups claiming familiarity to it.



Sign up for free insights from your sector…

Antispam code: 3426

Support Us...

We hope that you have found this article useful. This section is freely available for all to use. Please help support it by liking us or following us on our social media platforms:

Share this article...


For updated Pharmaceutical insights please follow us on @DJS_Pharma or use our RSS feed

Other Pharmaceutical Research Findings

Other Latest Market Research Insights

© DJS Research 2020